ATE275562T1 - Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen - Google Patents

Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE275562T1
ATE275562T1 AT99923712T AT99923712T ATE275562T1 AT E275562 T1 ATE275562 T1 AT E275562T1 AT 99923712 T AT99923712 T AT 99923712T AT 99923712 T AT99923712 T AT 99923712T AT E275562 T1 ATE275562 T1 AT E275562T1
Authority
AT
Austria
Prior art keywords
irbesartan
pharmaceutical compositions
compositions containing
obtaining
containing same
Prior art date
Application number
AT99923712T
Other languages
English (en)
Inventor
Bruno Franc
Christian Hoff
San Kiang
Mark D Lindrud
Olivier Monnier
Chenkou Wei
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9527829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE275562(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE275562T1 publication Critical patent/ATE275562T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AT99923712T 1998-06-24 1999-06-10 Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen ATE275562T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9808037A FR2780403B3 (fr) 1998-06-24 1998-06-24 Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
PCT/FR1999/001372 WO1999067236A1 (fr) 1998-06-24 1999-06-10 Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
ATE275562T1 true ATE275562T1 (de) 2004-09-15

Family

ID=9527829

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99923712T ATE275562T1 (de) 1998-06-24 1999-06-10 Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen

Country Status (25)

Country Link
US (2) US6800761B1 (de)
EP (1) EP1089994B9 (de)
JP (1) JP2002518495A (de)
KR (1) KR20010034917A (de)
CN (1) CN1127499C (de)
AT (1) ATE275562T1 (de)
AU (1) AU747887B2 (de)
BG (1) BG105069A (de)
BR (1) BR9912198A (de)
CA (1) CA2335545A1 (de)
CZ (1) CZ292868B6 (de)
DE (1) DE69920017T2 (de)
EA (1) EA003410B1 (de)
FR (1) FR2780403B3 (de)
HU (1) HUP0103913A3 (de)
ID (1) ID27377A (de)
IL (1) IL140419A0 (de)
NO (1) NO317786B1 (de)
NZ (1) NZ508842A (de)
PL (1) PL345215A1 (de)
SK (1) SK20032000A3 (de)
TR (1) TR200003842T2 (de)
UA (1) UA55540C2 (de)
WO (1) WO1999067236A1 (de)
ZA (1) ZA200007588B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176793A1 (en) * 2001-12-10 2005-08-11 Reddy Reguri B. Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one
ES2281312T3 (es) * 2003-01-16 2008-08-01 Teva Pharmaceutical Industries Ltd. Nueva sintesis de irbesartan.
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AU2007202693B2 (en) * 2003-01-20 2009-12-10 Novartis Ag Process for modifying drug crystal formation
PT1590343E (pt) * 2003-02-05 2008-09-11 Teva Pharma Síntese de 2-butil-3-(2¿-(1-tritil-1h-tetrazol-5-il)bifenil-4-il)-1,3-diazaspiro-4,4-non-en-4-ona
EP1660435A2 (de) * 2003-08-27 2006-05-31 Boehringer Ingelheim International GmbH Cycloalkylaminosäureverbindungen, verfahren zu deren herstellung und deren verwendung
US20090286990A1 (en) * 2004-05-20 2009-11-19 Reguri Buchi Reddy Process for preparing irbesartan
EP1750862B1 (de) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Irbesartan enthaltende pharmazeutische zusammensetzung
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
SI21848A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava seskvihidratne hidrokloridne soli tetrazolskega derivata
TWI346108B (en) * 2004-08-23 2011-08-01 Bristol Myers Squibb Co A method for preparing irbesartan and intermediates thereof
GB2419592A (en) 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
ES2454197T3 (es) * 2004-11-11 2014-04-09 Lek Pharmaceuticals D.D. Formas polimórficas de Irbesartán
PL1806130T3 (pl) 2006-01-09 2010-08-31 Krka D D Novo Mesto Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan
WO2008041957A1 (en) * 2006-10-03 2008-04-10 Ulkar Kimya Sanayi Ve Ticaret As Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
ES2377239T3 (es) * 2007-04-17 2012-03-23 Ratiopharm Gmbh Composiciones farmacéuticas que comprenden irbesartán
US9024009B2 (en) * 2007-09-10 2015-05-05 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
ATE474558T1 (de) * 2007-11-28 2010-08-15 Lesvi Laboratorios Sl Pharmazeutische formulierungen mit irbesartan
WO2009072137A2 (en) * 2007-12-07 2009-06-11 Hetero Drugs Limited Process for pure irbesartan
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CZ302407B6 (cs) * 2009-03-12 2011-05-04 Univerzita Pardubice Zpusob prípravy 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-onu
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
DK2451797T3 (da) 2009-07-10 2013-06-24 Janssen Pharmaceutica Nv Fremgangsmåde til krystallisation for 1-(b-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-fluorphenyl)-2- thienylmethyl]benzen
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
SG10201500258WA (en) * 2009-10-14 2015-03-30 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
JP5973551B2 (ja) 2011-04-13 2016-08-23 ヤンセン ファーマシューティカ エヌ．ベー． Ｓｇｌｔ２の阻害物質として有用な化合物の調製プロセス
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6851379B2 (ja) * 2015-12-21 2021-03-31 ヤンセン ファーマシューティカ エヌ．ベー． カナグリフロジン半水和物結晶を得るための結晶化手順

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
NZ237476A (en) * 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
FR2725987B1 (fr) 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Also Published As

Publication number Publication date
NO20006645L (no) 2001-02-26
ID27377A (id) 2001-04-05
EA003410B1 (ru) 2003-04-24
IL140419A0 (en) 2002-02-10
CN1127499C (zh) 2003-11-12
NZ508842A (en) 2002-09-27
NO317786B1 (no) 2004-12-13
US20050032862A1 (en) 2005-02-10
HUP0103913A3 (en) 2003-01-28
SK20032000A3 (sk) 2001-05-10
BR9912198A (pt) 2001-04-10
CN1306529A (zh) 2001-08-01
FR2780403B3 (fr) 2000-07-21
CZ20004771A3 (en) 2001-06-13
EA200001221A1 (ru) 2001-08-27
JP2002518495A (ja) 2002-06-25
BG105069A (en) 2001-11-30
DE69920017D1 (de) 2004-10-14
PL345215A1 (en) 2001-12-03
CA2335545A1 (en) 1999-12-29
AU4048499A (en) 2000-01-10
US7008959B2 (en) 2006-03-07
FR2780403A1 (fr) 1999-12-31
DE69920017T2 (de) 2005-09-22
AU747887B2 (en) 2002-05-30
TR200003842T2 (tr) 2001-06-21
EP1089994B9 (de) 2008-08-27
WO1999067236A1 (fr) 1999-12-29
KR20010034917A (ko) 2001-04-25
UA55540C2 (uk) 2003-04-15
EP1089994A1 (de) 2001-04-11
HUP0103913A2 (hu) 2002-03-28
CZ292868B6 (cs) 2003-12-17
US6800761B1 (en) 2004-10-05
ZA200007588B (en) 2001-06-11
NO20006645D0 (no) 2000-12-22
EP1089994B1 (de) 2004-09-08

Similar Documents

Publication Publication Date Title
ATE275562T1 (de) Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen
ATE235507T1 (de) Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE296823T1 (de) Substituierte heterocyclische verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE69813523D1 (de) Polyalkoxysiloxanverbindungen,verfahren zur herstellung und diese verbindungen enthaltende beschichtungszusammensetzungen
DE602004020332D1 (de) Neue heterozyklische verbindungen, die sich für die behandlung von entzündlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
DE69902535T2 (de) Phenoxypropanolamin-derivate, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen zusammensetzungen
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
DE69104991D1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
DE60023872D1 (de) Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung
ATE534656T1 (de) Neue oligosaccharide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE59707503D1 (de) Neue arylglycinamidderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE69325393D1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
DE19983660T1 (de) Verfahren zur Aufreinigung von Lösungsmitteln, die bei der Herstellung von pharmazeutischen Zusammensetzungen nützlich sind
ATE247645T1 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
DE60128112D1 (de) Aminoalkoxybenzoyl-benzofurane oder benzothiophene, verfahren zu ihrer herstellung und die enthaltenden zusammensetzungen
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE50204789D1 (de) Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EE05182B1 (et) Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
DE69931038D1 (de) Neue polysaccharidderivate, verfahren zu ihrer herstellung und medizinische zusammensetzungen die diese als aktives bestandteil enthalten
DE69619868T2 (de) Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung
BRPI0410026A (pt) derivados de 3-amino-croman quinolina
ATE323097T1 (de) Neue 5-thio-ss-d-xylopyranosidderivate, verfahren zu deren herstellung, diese enthaltende pharmazeutische zusammensetzungen und deren therapeutische verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties